康缘品牌怎么样 申请店铺

我要投票 康缘在中草药行业中的票数:200 更新时间:2025-04-20
康缘是哪个国家的品牌?「康缘」是 江苏康缘药业股份有限公司 旗下著名品牌。该品牌发源于江苏,由创始人肖伟在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康缘品牌出海!通过在本页面挂载康缘品牌的产品链接和联系邮箱,可以提高康缘产品曝光!跨境电商爆单神器,目前只要100元/年哦~

康缘怎么样

充满活力的创新型制药企业--江苏康缘药业股份有限公司是一家集中药研发、生产、贸易为一体的大型中药企业,是国家中药现代化示范企业、国家重点高新技术企业、国内A股上市公司、国家创新型企业,全国制药工业百强企业,获国家“质量管理先进企业”,“守合同重信用企业”等荣誉称号,“康缘”商标为国家驰名商标。

公司坚持以科研创新为先导,不断提升企业自主创新实力。企业设立博士后科研工作站、江苏省院士工作站,成立康缘现代中药研究院,拥有一支包括6名博士后、12名博士、80余名硕士在内的180多名科研人员组成的研究队伍;先后与中国医学科学院药物研究所、中科院上海有机化学研究所、大连工业大学等科研院所联合建立了十余个共建实验室,并在美国建立了创新药物研发公司,自主创新能力位居国内同行前列,发明专利授权量在同行业中名列前茅。2002年康缘药业被批准设立博士后科研工作站,2005年公司研发中心被认定为国家级企业技术中心。2010年1月康缘研究院被国家科技部批准建设“中药制药过程新技术国家重点实验室”,进入我国中医药创新体系国家队行列。

康缘药业拥有国内最大的智能化中药材提取生产线,具有年处理生药材10000吨的能力;拥有通过国家GMP验证的制剂车间,配套完善的备料中心、质量检测中心、动力中心、智能管理中心,设有硬胶囊、软胶囊、小容量注射剂、冻干粉针剂等十三条最先进的生产线,具备年生产硬胶囊12亿粒、软胶囊3.4亿粒、口服液1亿支、小容量注射剂5亿支、冻干粉针剂600万支、片剂15亿片、颗粒剂1000吨的能力。

康缘药业全力推行专业化、学术化营销,建立了一支高素质、专业化1600余人的营销队伍,在全国29个省市建立了34个销售分公司、226多个中心办事处,与全国146家医药商业公司建立了长期稳定的业务关系,产品覆盖近7000家县级以上医疗单位。

Jiangsu Kangyuan Pharmaceutical Co., Ltd., a dynamic and innovative pharmaceutical enterprise, is a large-scale Chinese medicine enterprise integrating research and development, production and trade of traditional Chinese medicine. It is a national modern demonstration enterprise of traditional Chinese medicine, a national key high-tech enterprise, A-share listed company, a national innovative enterprise, and one of the top 100 pharmaceutical enterprises in China, It has won the honorary titles of "advanced quality management enterprise", "contract abiding and trustworthy enterprise" and "Kangyuan" trademark is a national well-known trademark. The company adheres to scientific research and innovation as the guide, and constantly improves the independent innovation strength of the enterprise. The company has set up postdoctoral research station, Jiangsu academician workstation, and Kangyuan modern Chinese Medicine Research Institute. It has a research team of more than 180 researchers, including 6 postdoctoral, 12 doctors, and more than 80 masters. It has been jointly built with the Institute of medicine of Chinese Academy of Medical Sciences, Shanghai Institute of organic chemistry of Chinese Academy of Sciences, Dalian University of technology and other research institutes More than ten co built laboratories have been set up, and innovative drug R & D companies have been established in the United States. The independent innovation ability ranks in the forefront of domestic peers, and the amount of invention patent authorization ranks first in the same industry. In 2002, Kangyuan pharmaceutical was approved to set up a postdoctoral research workstation, and in 2005, the company's R & D center was recognized as a national enterprise technology center. In January 2010, Kangyuan Research Institute was approved by the Ministry of science and technology of the people's Republic of China to build the "National Key Laboratory of new technology in the pharmaceutical process of traditional Chinese medicine", and entered the ranks of the national team of Chinese medicine innovation system. Kangyuan Pharmaceutical Co., Ltd. has the largest intelligent production line of Chinese herbal medicine extraction in China, with an annual capacity of 10000 tons of raw herbs. It has a preparation workshop certified by the national GMP, a complete set of material preparation center, quality inspection center, power center, intelligent management center, and 13 most advanced production lines, including hard capsule, soft capsule, small volume injection, freeze-dried powder injection, It has the annual production capacity of 1.2 billion hard capsules, 340 million soft capsules, 100 million oral liquids, 500 million small volume injections, 6 million lyophilized powder injections, 1.5 billion tablets and 1000 tons of granules. Kangyuan pharmaceutical industry has made great efforts to promote professional and academic marketing, established a high-quality and professional marketing team of more than 1600 people, established 34 sales branches and more than 226 central offices in 29 provinces and cities across the country, established long-term and stable business relations with 146 pharmaceutical commercial companies across the country, with products covering nearly 7000 medical units above the county level.

本文链接: https://brand.waitui.com/0310949a5.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

后视摄像头图像无法显示,克莱斯勒在美召回48494辆汽车

当地时间4月19日,美国国家公路交通安全管理局(NHTSA)文件披露,由于显示模块可能无法显示后视摄像头图像,克莱斯勒将召回部分2023-2025年款阿尔法·罗密欧Tonale托纳利和道奇大黄蜂,共计48494辆。(界面)

53分钟前

一季度北京地区进出口7198.9亿元 汽车产业拉动出口增长

4月19日,据北京海关消息,今年一季度北京地区(含中央在京单位)进出口7198.9亿元。其中,出口1480.9亿元,较去年同期增长2.2%。北京外贸含“新”量进一步提升。一季度,北京地区汽车产业出口128.1亿元,同比增长56%,上拉同期地区出口增速3.2个百分点,拉动作用最强。同期,医药健康产业、绿色低碳产业分别出口31.6亿元、19亿元,同比分别增长5.8%、119.1%。

53分钟前

上海国际集团与宝山区签署战略合作框架协议 支持绿色低碳、新材料、机器人等发展

4月19日,上海国际集团与宝山区签署战略合作框架协议。双方将通过北转型基金提级扩募,重点支持宝山绿色低碳、新材料、机器人及智能制造等主导产业发展,以全链条金融服务赋能科创产业升级,并加强上市平台培育。(财联社)

53分钟前

一季度重庆外贸进出口总值1651.4亿元 同比增长4.1%

4月19日,重庆海关发布消息称,2025年一季度,重庆外贸进出口总值为1651.4亿元(人民币,下同),同比增长4.1%。据重庆海关介绍,2025年一季度,东盟是重庆第一大贸易伙伴,进出口281.4亿元,同比增长10.5%。此外,重庆对拉美、中东、非洲等新兴市场分别同比增长30.9%、9.2%、41.2%,外贸“朋友圈”持续扩大。

53分钟前

改善患者肢体运动功能 “植入式迷走神经刺激系统”临床试验启动

4月19日,国家卫生健康委组织实施“百万减残”工程重点推广项目,我国自主研发的“植入式迷走神经刺激系统”临床试验正式全国启动。该项目有望成为我国卒中后残疾防控的重要手段。迷走神经电刺激作为一种微创手术,可以辅助脑卒中患者康复治疗。数据显示,该技术能够在卒中后康复黄金期6月以后,帮助患者持续重建神经功能,明显改善患侧肢体运动功能。(财联社)

53分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询